TITLE

Legacy Content Migrations while Maintaining Government and International Standards Compliance

AUTHOR(S)
Rothe, Jay
PUB. DATE
July 2009
SOURCE
Infonomics;Jul/Aug2009, Vol. 23 Issue 4, p30
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents case studies related to content migrations in the biopharmaceutical industry in the U.S. It points on the case of Purdue Pharma LP and the problems it encountered when it deployed the Document 3 document management system as well as its success in migrating older clinical trial data. Another biomedical and biopharmaceutical company uses software from Plumtree Inc. in merging document management to its central system for easier access to information by its staff.
ACCESSION #
43638070

 

Related Articles

  • CASE STUDY: IMPACT SYSTEMS DEPLOYS COMPLIANCE IN-A-BOXâ„¢ SOP EDITION AND COMPLIANCEIN-A-BOXâ„¢ SUBMISSION EDITION FOR LUNG RX.  // Infonomics;Jul/Aug2009, Vol. 23 Issue 4, p38 

    The article presents a case study on the use of different software from Impact Systems Inc. for Lung Rx, a biotechnology company in the U.S. Impact Systems Inc., software provider, deploys the Compliance-in-a-Box Standard Operating Procedure Edition and the Compliance-in-a-Box Submission Edition...

  • Electronic Endpoint Adjudication. Tyner, Cathy; El-Assi, Zaher // Applied Clinical Trials;Mar2010 Supplement, p10 

    The article discusses the significance of electronic endpoint adjudication system (EAS) to biopharmaceutical and medical device companies in the U.S. It mentions that the system is advantageous to firms because it speeds up data collection of clinical trials, cleans up and manages the process by...

  • Regular Review: Clinical experimentation in obstetrics. Lilford, R.J. // British Medical Journal (Clinical Research Edition);11/21/1987, Vol. 295 Issue 6609, p1298 

    Describes clinical experimentation in obstetrics. Selection of control patients; Problems of obstetrician-scientists; Acceptance of randomized trials.

  • 45-Year-Old Female with a 25 Year History of Seizures. AlSufiani, Fahd M.; Burneo, Jorge G.; McLachlan, Richard S.; Pelz, David M.; Steven, David A.; Hammond, Robert R. // Canadian Journal of Neurological Sciences;Jan2013, Vol. 40 Issue 1, p85 

    The article presents a case study of a 45-year-old female who was diagnosed with a 25-year history of seizures. It mentions that trials of antiepileptic drugs (AEDs) were performed. The article also notes a radial angiocentric architecture with perivascular pseudorosettes within the patient's...

  • Going Global Without Sacrificing Consistency and Quality in Clinical Trials. Meinert, Lawrence A. // Pharma DD: Tracking Discovery & Development;Jan/Feb2007, Vol. 2 Issue 1, p34 

    In the past thirty years, drug companies involved in late-stage drug development have initiated Phase II testing in humans in clinical research units typically located in the United States, the United Kingdom, Canada, and Western Europe. However, an increasingly intense competitive environment'...

  • Masitinib.  // Reactions Weekly;Oct2015, Vol. 1574 Issue 1, p171 

    The article presents a case study of a 40-year-old woman who developed drug-induced liver injury after being treated with masitinib.

  • Europe's drug agency will publish all clinical trial data from 2014. Torjesen, Ingrid // BMJ: British Medical Journal;12/1/2012, Vol. 345 Issue 7885, p4 

    The article reports that the European Medicines Agency will be publishing full clinical trial data submitted by companies for a clinical product after completing the marketing authorization process.

  • Neonatal extracorporeal membrane oxygenation (ECMO): clinical trials and the ethics of evidence. Mike, Valerie; Krauss, Alfred N. // Journal of Medical Ethics;Dec93, Vol. 19 Issue 4, p212 

    Presents a case study on neonatal extracorporeal membrane oxygenation (ECMO) to examine statistical and ethical aspects of clinical trials. Background account on ECMO; Conceptual framework for ethics of evidence; Medical uncertainty in broader perspective; Conclusion.

  • Drug safety alerts move to the Internet.  // Contemporary OB/GYN;Sep2008, Vol. 53 Issue 9, p23 

    The article offers information on the Health Care Notification Network (HCNN), an online network designed to inform physicians of drug safety alerts.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics